MCID: ORL007
MIFTS: 52

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15 17
Malignant Neoplasm of Floor of Mouth 12 32
Malignant Neoplasm of Mouth 70
Oral Cavity Carcinoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8618
ICD9CM 34 144 144.0 144.1
NCIt 50 C9318
UMLS 70 C0151546 C0153368 C0153369 more

Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of floor of mouth, is related to salivary gland carcinoma and oral cancer. An important gene associated with Oral Cavity Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dexamethasone and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include the, lymph node and tongue, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 salivary gland carcinoma 32.4 SOX2 MDM2 GSTM1 ERBB2 EGFR CDKN2A
2 oral cancer 32.0 MDM2 GSTM1 EGFR CYP1A1 CDKN2A
3 oropharynx cancer 31.5 ERBB2 EGFR CDKN2A CASP8
4 papilloma 31.2 VEGFA IL4 ERBB2 EGFR CDKN2A
5 squamous cell carcinoma 31.1 VEGFA TNFRSF10B ERBB2 EGFR CYP1A1 CDKN2A
6 tonsil cancer 30.9 ERBB2 EGFR CDKN2A
7 tongue squamous cell carcinoma 30.6 VEGFA SOX2 EGFR CDKN2A
8 squamous cell carcinoma, head and neck 30.5 VEGFA TNFRSF10B MCL1 GSTM1 ERBB2 EGFR
9 esophageal cancer 30.4 VEGFA SOX2 MDM2 GSTM1 ERCC1 ERBB2
10 lip and oral cavity cancer 11.3
11 oral squamous cell carcinoma 11.2
12 esophagus verrucous carcinoma 10.6 MDM2 EGFR CDKN2A
13 verrucous carcinoma 10.6 MDM2 EGFR CDKN2A
14 parotid gland adenoid cystic carcinoma 10.6 ERBB2 CDKN2A
15 toxic oil syndrome 10.6 IL4 GSTM1 CYP1A1
16 soft tissue sarcoma 10.6 VEGFA MDM2 EGFR
17 small cell carcinoma 10.6 ERBB2 EGFR CDKN2A
18 lung non-squamous non-small cell carcinoma 10.6 VEGFA ERBB2 EGFR
19 vulvar disease 10.6 ERBB2 EGFR CDKN2A
20 gastroesophageal junction adenocarcinoma 10.6 VEGFA ERBB2 EGFR
21 mediastinum liposarcoma 10.6 MDM2 CDKN2A
22 proliferative verrucous leukoplakia 10.6 TLR2 CDKN2A
23 infiltrating angiolipoma 10.6 VEGFA MDM2 CDKN2A
24 placental site trophoblastic tumor 10.6 VEGFA ERBB2 EGFR
25 sapho syndrome 10.6 VEGFA MDM2 IL18
26 malignant peritoneal mesothelioma 10.6 EGFR CDKN2A
27 gliomatosis cerebri 10.6 MDM2 EGFR CDKN2A
28 cardia cancer 10.6 MDM2 GSTM1 CYP1A1
29 basaloid squamous cell carcinoma 10.6 SOX2 EGFR CDKN2A
30 exanthem 10.6 VEGFA IL18 ERBB2 EGFR
31 gastroesophageal adenocarcinoma 10.6 GSTM1 ERCC1 ERBB2 EGFR
32 vulva basal cell carcinoma 10.6 ERBB2 CDKN2A
33 esophagus adenocarcinoma 10.6 ERBB2 EGFR CDKN2A
34 breast scirrhous carcinoma 10.6 ERBB2 EGFR
35 mucinous adenocarcinoma 10.6 VEGFA ERBB2 EGFR CDKN2A
36 oral submucous fibrosis 10.6 VEGFA GSTM1 CYP1A1
37 pancreatic ductal carcinoma 10.6 VEGFA ERBB2 EGFR CDKN2A
38 primary peritoneal carcinoma 10.6 VEGFA ERCC1 ERBB2 EGFR
39 rosacea 10.6 VEGFA TLR2 IL18 GSTM1
40 pre-malignant neoplasm 10.6 VEGFA ERBB2 EGFR CDKN2A
41 childhood medulloblastoma 10.6 ERBB2 EGFR CDKN2A CASP8
42 neurofibroma 10.6 VEGFA ERBB2 EGFR CDKN2A
43 endometrial adenocarcinoma 10.6 VEGFA ERBB2 EGFR CDKN2A
44 ovarian cystadenocarcinoma 10.6 ERBB2 EGFR CDKN2A
45 suppression of tumorigenicity 12 10.5 VEGFA ERBB2 EGFR CDKN2A
46 vulva cancer 10.5 ERBB2 EGFR CDKN2A
47 mycoplasma pneumoniae pneumonia 10.5 TLR2 IL4 IL18 CYP1A1
48 amelogenesis imperfecta, type ig 10.5 VEGFA ERBB2 EGFR CYP1A1
49 ductal carcinoma in situ 10.5 VEGFA ERBB2 EGFR CDKN2A
50 pneumoconiosis 10.5 SOD2 IL4 GSTM1 CASP8

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 CDKN2A FADD IL18 MCL1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 BAX CDKN2A ERCC1 FADD IL18 MCL1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.47 BAX CASP8 ERCC1 MCL1

MGI Mouse Phenotypes related to Oral Cavity Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 BAX CASP8 CDKN2A EDNRB EGFR ERBB2
2 growth/size/body region MP:0005378 10.51 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
3 homeostasis/metabolism MP:0005376 10.49 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
4 hematopoietic system MP:0005397 10.47 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
5 endocrine/exocrine gland MP:0005379 10.46 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
6 mortality/aging MP:0010768 10.46 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
7 immune system MP:0005387 10.45 BAX CASP8 CDKN2A CYP1A1 EDNRB EGFR
8 cardiovascular system MP:0005385 10.42 CASP8 CDKN2A EDNRB EGFR ERBB2 FADD
9 behavior/neurological MP:0005386 10.4 BAX CDKN2A EDNRB ERBB2 ERCC1 GDF15
10 nervous system MP:0003631 10.39 BAX CASP8 CDKN2A EDNRB EGFR ERBB2
11 integument MP:0010771 10.38 CASP8 CDKN2A EDNRB EGFR ERBB2 ERCC1
12 digestive/alimentary MP:0005381 10.34 CDKN2A EDNRB EGFR ERBB2 FADD IL18
13 muscle MP:0005369 10.34 BAX CASP8 CDKN2A EDNRB EGFR ERBB2
14 embryo MP:0005380 10.33 CASP8 CDKN2A EDNRB EGFR ERBB2 ERCC1
15 liver/biliary system MP:0005370 10.3 CASP8 CDKN2A CYP1A1 EGFR ERCC1 FADD
16 neoplasm MP:0002006 10.26 BAX CASP8 CDKN2A EDNRB EGFR ERBB2
17 normal MP:0002873 10.06 CYP1A1 EGFR ERBB2 IL4 MCL1 MDM2
18 renal/urinary system MP:0005367 10.06 BAX CASP8 EDNRB EGFR ERCC1 GDF15
19 no phenotypic analysis MP:0003012 10.03 CDKN2A CYP1A1 EGFR FADD IL4 MDM2
20 reproductive system MP:0005389 10.03 BAX CDKN2A EGFR ERBB2 ERCC1 FADD
21 pigmentation MP:0001186 9.85 CDKN2A EDNRB EGFR MDM2 SOD2 SOX2
22 respiratory system MP:0005388 9.85 BAX CASP8 CDKN2A EDNRB EGFR ERBB2
23 skeleton MP:0005390 9.73 BAX CDKN2A EDNRB EGFR ERBB2 ERCC1
24 vision/eye MP:0005391 9.36 BAX CDKN2A EDNRB EGFR ERCC1 IL18

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
2
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
4
Thalidomide Approved, Investigational, Withdrawn Phase 2, Phase 3 50-35-1 5426
5 Angiogenesis Inhibitors Phase 2, Phase 3
6 Gastrointestinal Agents Phase 2, Phase 3
7 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
8 Analgesics, Non-Narcotic Phase 2, Phase 3
9 Antiemetics Phase 2, Phase 3
10 Anti-Infective Agents Phase 2, Phase 3
11 Analgesics Phase 2, Phase 3
12 Cyclooxygenase Inhibitors Phase 2, Phase 3
13 Hormones Phase 2, Phase 3
14 Hormone Antagonists Phase 2, Phase 3
15 glucocorticoids Phase 2, Phase 3
16 Antineoplastic Agents, Hormonal Phase 2, Phase 3
17 Anti-Bacterial Agents Phase 2, Phase 3
18 Anti-Inflammatory Agents Phase 2, Phase 3
19 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
20
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
23
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
24
Pembrolizumab Approved Phase 2 1374853-91-4
25
nivolumab Approved Phase 2 946414-94-4
26 Tubulin Modulators Phase 2
27 Antimitotic Agents Phase 2
28 Antibodies Phase 2
29 Immunoglobulins Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Immunoglobulins, Intravenous Phase 2
32 Antibodies, Monoclonal Phase 2
33
Ethanol Approved 64-17-5 702
34
Cocaine Approved, Illicit Early Phase 1 50-36-2 446220 5760
35
Tyrosine Approved, Investigational, Nutraceutical Early Phase 1 60-18-4 6057
36
Lobeline Investigational 90-69-7

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
2 Multicentre,A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
3 A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes Unknown status NCT03121313 Phase 2 tegafur-uracil
4 Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response Completed NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
5 Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment Completed NCT00780312 Phase 2
6 A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 Completed NCT01116843 Phase 1, Phase 2 PF-00299804
7 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
8 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
9 Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent Recruiting NCT04330781 Phase 2
10 A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT03422536 Phase 2 Ficlatuzumab
11 Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Active, not recruiting NCT02882282 Phase 2
12 Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Active, not recruiting NCT03021993 Phase 2 Nivolumab
13 NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Active, not recruiting NCT03721757 Phase 2
14 A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization Not yet recruiting NCT04065737 Phase 2 Sintilimab
15 A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx. Completed NCT01140178 Phase 1 HPPH
16 Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck Withdrawn NCT00006106 Phase 1 cisplatin;fluorouracil;ONYX-015
17 Phase I Neo-Adjuvant Nivolumab + IRX-2 Followed by Surgery for Resectable Oral Cavity Cancer or HPV-Associated Oropharynx Cancer Withdrawn NCT03575234 Phase 1 Cyclophosphamide
18 The Feasibility of Circulating Tumor Cells Isolation for Transcriptomes and Genome-wide Associated Analysis in Post-surgically High-risk Oral Cavity Cancer Patients and Its Clinical Significance. Unknown status NCT03917524
19 Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents: A Cluster-Randomized Trial Completed NCT03488095
20 A Prospective Examination of Smoking Status and Body Image in Surgical Patients With Cancer of the Oral Cavity Completed NCT00412490
21 Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients Completed NCT02412241
22 Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW) Completed NCT03575598 Early Phase 1 Sitravatinib
23 Randomized Intervention Trial to Evaluate Oral Visual Inspection in the Control of Oral Cancer Completed NCT04494620
24 CytID Analysis of Oral Lesions Recruiting NCT03555721
25 Screening for Cancers in the Oral CAvity Targeting Tobacco Users in Somme, France Recruiting NCT01958762
26 Narrow Band Imaging in Oral Cavity Cancer-defining the Tumour Border Recruiting NCT04398121
27 A Multicenter Prospective Phase II Study of Postoperative Hypofractionated Stereotactic Body Radiotherapy (SBRT) in the Treatment of Early Stage Oropharyngeal and Oral Cavity Cancers With High Risk Margins. Recruiting NCT03401840
28 Intra-operative Gross Examination Versus Frozen Section for Achievement of Adequate Margin in Patients Undergoing Surgery for Oral Cavity Squamous Cell Carcinoma: A Randomized Controlled Trial Not yet recruiting NCT04809324

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Anatomical Context for Oral Cavity Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The

MalaCards organs/tissues related to Oral Cavity Cancer:

40
Lymph Node, Tongue, Skin, Bone, Skeletal Muscle, Lung, Thyroid

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 960)
# Title Authors PMID Year
1
Relationship between the prevalence of oral human papillomavirus DNA and periodontal disease (Review). 61
33728046 2021
2
Margin Practices in Oral Cavity Cancer Resections: Survey of American Head and Neck Society Members. 61
32827312 2021
3
Long non-coding RNA OIP5-AS1 contributes to cisplatin resistance of oral squamous cell carcinoma through the miR-27b-3p/TRIM14 axis. 61
33692839 2021
4
Distant metastasis from oral cavity-correlation between histopathology results and primary site. 61
32468449 2021
5
The diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma: a systematic review and diagnostic meta-analysis. 61
32949282 2021
6
Adjuvant contralateral neck irradiation for oral cavity cancer - A systematic review and meta-analysis. 61
33476968 2021
7
Delayed presentation of head and neck cancer patients during COVID-19 pandemic. 61
33674926 2021
8
Preoperative prognostic nutritional index predicts prognosis of patients with oral cavity cancer. 61
33690959 2021
9
Comparative prognostic value of different preoperative complete blood count cell ratios in patients with oral cavity cancer treated with surgery and postoperative radiotherapy. 61
33624454 2021
10
Determinants of delay and association with outcome in head and neck cancer: A systematic review. 61
33715909 2021
11
Chemoradiation therapy changes oral microbiome and metabolomic profiles in patients with oral cavity cancer and oropharyngeal cancer. 61
33527579 2021
12
Improved local control in p16 negative oropharyngeal cancers with hypermethylated MGMT. 61
33577867 2021
13
Clinicopathological characteristics of young never smoker females with oral cavity squamous cell carcinoma: A STROBE compliant retrospective observational study. 61
33592842 2021
14
Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: A longitudinal study. 61
33621588 2021
15
The emergence of oral cavity cancer and the stabilization of oropharyngeal cancer: Recent contrasting epidemics in the South Korean population. 61
33595858 2021
16
Elective neck dissection versus positron emission tomography-computed tomography-guided management of the neck in clinically node-negative early oral cavity cancer: A cost-utility analysis. 61
33635537 2021
17
Perineural Invasion As the Sole Pathologic Risk Factor After Surgical Resection for Head and Neck Squamous Cell Carcinoma. 61
33692913 2021
18
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient. 61
33470618 2021
19
Tumor subsites and risk of osteoradionecrosis of the jaw in patients with oral cavity cancer: a national-based cohort study. 61
33389009 2021
20
Improving oral cavity cancer diagnosis and treatment with fluorescence molecular imaging. 61
32072691 2021
21
Oral squamous cell carcinoma resection and neck dissection mortality: a 10-year national audit study. 61
33244898 2021
22
To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer? 61
33648773 2021
23
Gender and race interact to influence survival disparities in head and neck cancer. 61
33232879 2021
24
Determinants of quality of life from the perspective of the patients: A qualitative analysis of patients with oral cavity cancer. 61
33277161 2021
25
Prognostic Value of Third Cervical Vertebra Skeletal Muscle Index in Oral Cavity Cancer: A Retrospective Study. 61
33433021 2021
26
Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. 61
32974936 2021
27
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques. 61
33777764 2021
28
Screening for malnutrition in oral cavity cancer patients prior to treatment: A cross-sectional study. 61
33484535 2021
29
Retrospective study on the potential of albumin/globulin ratio as a prognostic biomarker for oral cavity cancer patients. 61
32583177 2021
30
Contralateral lymph node recurrence rate and its prognostic factors in stage IVA-B well-lateralized oral cavity cancer. 61
33526320 2021
31
Customized 3D Bolus Applied to the Oral Cavity and Supraclavicular Area for Head and Neck Cancer. 61
33402512 2021
32
The influence of cervical lymph node number of neck dissection on the prognosis of the early oral cancer patients. 61
33505625 2020
33
Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer. 61
33369477 2020
34
Toothbrushing frequency and gastric and upper aerodigestive tract cancer risk: A meta-analysis. 61
33349957 2020
35
Acquiring guideline-enabled data driven clinical knowledge model using formally verified refined knowledge acquisition method. 61
32882592 2020
36
The Inequitable Global Burden of Lip and Oral Cancers: Widening Disparities Across Countries. 61
33497647 2020
37
Evolving Evidence in Support of Sentinel Lymph Node Biopsy for Early-Stage Oral Cavity Cancer. 61
33052758 2020
38
Time to Start Asking the Right Question or at Least Admit We Do Not Have the Answer-Indications for Elective Neck Dissection in Early-Stage Oral Cavity Cancer. 61
32771445 2020
39
Oral Cavity Cancer Outcomes in Remote, Betel Nut-Endemic Pacific Islands. 61
32546006 2020
40
Prediction of cervical metastasis and survival in cN0 oral cavity cancer using tumour 18F-FDG PET/CT functional parameters. 61
32642973 2020
41
Lymph node ratio in oral cavity cancer and its impact on mortality and disease recurrence. 61
32660895 2020
42
Trends in mortality rates for oral and oropharyngeal cancer in Spain, 1979-2018. 61
33305413 2020
43
The Role of Age and Merkel Cell Polyomavirus in Oral Cavity Cancers. 61
32571145 2020
44
Oral cavity cancer management during the COVID-19 pandemic. 61
33377460 2020
45
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. 61
32671504 2020
46
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. 61
32932276 2020
47
Nuclear F-actin Cytology in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. 61
33179547 2020
48
Sarcopenia and Systemic Inflammation Synergistically Impact Survival in Oral Cavity Cancer. 61
33135827 2020
49
Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers. 61
33180128 2020
50
Prognostic factors analysis for oral cavity cancer survival in the Netherlands and Taiwan using a privacy-preserving federated infrastructure. 61
33239719 2020

Variations for Oral Cavity Cancer

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VEGFA TLR2 SOX2 MDM2 MCL1 IL4
2
Show member pathways
13.67 TNFRSF10B SOD2 IL4 IL18 GDF15 ERBB2
3
Show member pathways
13.61 VEGFA TNFRSF10B SOX2 MDM2 IL4 IL18
4
Show member pathways
13.54 VEGFA TNFRSF10B IL4 IL18 GDF15 ERBB2
5
Show member pathways
13.36 VEGFA SOX2 MCL1 IL4 IL18 ERBB2
6
Show member pathways
13.36 TNFRSF10B TLR2 MDM2 IL4 IL18 GDF15
7
Show member pathways
13.29 TNFRSF10B IL4 IL18 GDF15 ERBB2 EGFR
8
Show member pathways
13.13 TNFRSF10B TLR2 SOD2 IL18 FADD EGFR
9
Show member pathways
12.87 VEGFA MDM2 ERBB2 EGFR CDKN2A BAX
10
Show member pathways
12.86 VEGFA TLR2 MDM2 FADD EGFR CDKN2A
11
Show member pathways
12.8 TNFRSF10B TLR2 MDM2 IL18 FADD CASP8
12
Show member pathways
12.76 GSTM1 ERBB2 EGFR CDKN2A BAX
13
Show member pathways
12.73 TNFRSF10B TLR2 IL18 FADD CASP8 BAX
14
Show member pathways
12.7 MDM2 FADD ERCC1 CASP8 BAX
15
Show member pathways
12.69 VEGFA TLR2 MDM2 MCL1 IL4 FADD
16
Show member pathways
12.68 MDM2 ERBB2 EGFR CDKN2A BAX
17
Show member pathways
12.66 TNFRSF10B MDM2 MCL1 FADD CDKN2A CASP8
18
Show member pathways
12.61 VEGFA MDM2 ERBB2 EGFR BAX
19 12.54 VEGFA MDM2 MCL1 ERBB2 EGFR CDKN2A
20
Show member pathways
12.44 MDM2 ERBB2 EGFR CASP8 BAX
21 12.42 VEGFA MDM2 IL4 GSTM1 FADD ERBB2
22 12.4 MDM2 IL18 EGFR BAX
23 12.39 VEGFA ERBB2 EGFR EDNRB
24
Show member pathways
12.38 TNFRSF10B MDM2 CDKN2A CASP8 BAX
25
Show member pathways
12.33 TLR2 IL4 FADD CASP8
26
Show member pathways
12.31 MDM2 ERBB2 EGFR BAX
27 12.3 MDM2 CDKN2A CASP8 BAX
28 12.29 VEGFA TLR2 MDM2 ERBB2 EGFR
29
Show member pathways
12.26 TNFRSF10B MDM2 CASP8 BAX
30 12.23 TLR2 IL18 FADD CASP8 BAX
31
Show member pathways
12.21 TNFRSF10B FADD CASP8 BAX
32 12.19 VEGFA TLR2 EGFR BAX
33 12.18 TNFRSF10B MCL1 GDF15 FADD CASP8 BAX
34
Show member pathways
12.03 TLR2 ERBB2 EGFR CASP8
35 12.03 VEGFA MDM2 FADD EGFR CASP8 BAX
36 11.99 SOD2 MDM2 ERBB2 CDKN2A BAX
37 11.98 VEGFA SOX2 MCL1 IL4 IL18
38 11.85 TNFRSF10B MDM2 MCL1 GDF15 EGFR BAX
39
Show member pathways
11.81 MCL1 FADD CASP8 BAX
40 11.8 MDM2 IL4 BAX
41 11.67 VEGFA MDM2 ERBB2 EGFR CDKN2A
42 11.62 TLR2 IL18 CASP8
43 11.59 VEGFA MDM2 CDKN2A
44 11.57 MCL1 EGFR CDKN2A BAX
45 11.53 EGFR CYP1A1 BAX
46 11.52 VEGFA EGFR CYP1A1
47 11.51 TNFRSF10B FADD CASP8
48 11.49 MDM2 CASP8 BAX
49 11.47 FADD CASP8 BAX
50
Show member pathways
11.44 MCL1 CASP8 BAX

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 9.58 TLR2 FADD CASP8
2 cytoplasm GO:0005737 9.55 VEGFA TLR2 SOX2 SOD2 MDM2 MCL1
3 Bcl-2 family protein complex GO:0097136 9.37 MCL1 BAX
4 membrane raft GO:0045121 9.35 TLR2 FADD EGFR EDNRB CASP8
5 death-inducing signaling complex GO:0031264 9.32 FADD CASP8
6 ripoptosome GO:0097342 9.26 FADD CASP8
7 CD95 death-inducing signaling complex GO:0031265 9.16 FADD CASP8

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 VEGFA TNFRSF10B TLR2 IL4 IL18 GDF15
2 positive regulation of cell proliferation GO:0008284 10.08 VEGFA MDM2 IL4 ERBB2 EGFR EDNRB
3 positive regulation of apoptotic process GO:0043065 10.04 TNFRSF10B FADD CDKN2A CASP8 BAX
4 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 VEGFA TLR2 SOX2 MDM2 IL4 IL18
5 cytokine-mediated signaling pathway GO:0019221 10 VEGFA SOX2 MCL1 IL4 IL18
6 negative regulation of apoptotic process GO:0043066 10 VEGFA SOD2 MDM2 MCL1 IL4 EGFR
7 positive regulation of cell migration GO:0030335 9.99 VEGFA SOD2 IL4 EGFR
8 positive regulation of protein phosphorylation GO:0001934 9.97 VEGFA ERBB2 EGFR EDNRB
9 regulation of apoptotic process GO:0042981 9.97 TNFRSF10B MCL1 FADD CASP8 BAX
10 response to hypoxia GO:0001666 9.95 VEGFA TLR2 SOD2 CYP1A1
11 positive regulation of gene expression GO:0010628 9.95 VEGFA TLR2 MDM2 IL4 IL18 ERBB2
12 cell proliferation GO:0008283 9.92 IL18 ERCC1 CYP1A1 BAX
13 apoptotic process GO:0006915 9.92 TNFRSF10B TLR2 MDM2 MCL1 FADD CDKN2A
14 positive regulation of protein kinase B signaling GO:0051897 9.91 VEGFA IL18 GDF15 ERBB2 EGFR
15 cell surface receptor signaling pathway GO:0007166 9.91 TNFRSF10B FADD ERBB2 EGFR EDNRB CASP8
16 positive regulation of MAPK cascade GO:0043410 9.89 VEGFA SOX2 GDF15 ERBB2
17 response to lipopolysaccharide GO:0032496 9.88 TLR2 SOD2 EDNRB CYP1A1 CASP8
18 response to wounding GO:0009611 9.87 SOX2 CYP1A1 BAX
19 apoptotic signaling pathway GO:0097190 9.86 FADD CASP8 BAX
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 VEGFA IL4 IL18
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TLR2 IL18 EGFR
22 cellular response to growth factor stimulus GO:0071363 9.85 MDM2 ERBB2 EGFR
23 response to toxic substance GO:0009636 9.85 TLR2 MDM2 CYP1A1 BAX
24 positive regulation of epithelial cell proliferation GO:0050679 9.84 VEGFA ERBB2 EGFR
25 cellular response to mechanical stimulus GO:0071260 9.84 TNFRSF10B FADD EGFR CASP8
26 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA ERBB2 EGFR
27 extrinsic apoptotic signaling pathway GO:0097191 9.8 FADD CASP8 BAX
28 cellular response to organic cyclic compound GO:0071407 9.8 MDM2 IL18 CYP1A1 CASP8
29 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.79 TNFRSF10B FADD CASP8
30 response to antibiotic GO:0046677 9.76 MDM2 CYP1A1 CASP8
31 response to immobilization stress GO:0035902 9.74 SOD2 ERCC1 CYP1A1
32 amyloid fibril formation GO:1990000 9.7 MDM2 CDKN2A
33 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.7 SOX2 BAX
34 toll-like receptor 3 signaling pathway GO:0034138 9.7 FADD CASP8
35 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.7 TNFRSF10B FADD CASP8
36 hydrogen peroxide biosynthetic process GO:0050665 9.68 SOD2 CYP1A1
37 death-inducing signaling complex assembly GO:0071550 9.67 FADD CASP8
38 regulation of necroptotic process GO:0060544 9.66 FADD CASP8
39 hydrogen peroxide metabolic process GO:0042743 9.66 SOD2 EGFR
40 negative regulation of ERBB signaling pathway GO:1901185 9.65 ERBB2 EGFR
41 type 2 immune response GO:0042092 9.64 IL4 IL18
42 negative regulation of immature T cell proliferation in thymus GO:0033088 9.63 ERBB2 CDKN2A
43 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.62 CASP8 BAX
44 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.46 MCL1 IL4 FADD BAX
45 TRAIL-activated apoptotic signaling pathway GO:0036462 9.43 TNFRSF10B FADD CASP8
46 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.35 TNFRSF10B FADD CDKN2A CASP8 BAX
47 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 8.92 TNFRSF10B FADD CASP8 BAX

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 VEGFA TNFRSF10B TLR2 SOX2 SOD2 MDM2
2 enzyme binding GO:0019899 9.77 SOD2 MDM2 GSTM1 EGFR CYP1A1
3 cytokine activity GO:0005125 9.71 VEGFA IL4 IL18 GDF15
4 BH3 domain binding GO:0051434 9.32 MCL1 BAX
5 identical protein binding GO:0042802 9.28 VEGFA TLR2 SOD2 MDM2 FADD ERBB2
6 receptor serine/threonine kinase binding GO:0033612 9.26 MDM2 FADD
7 death effector domain binding GO:0035877 9.16 FADD CASP8

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....